Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes

Bibliography

• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999–3054
   PubMed Web of Science ®Google Scholar
• Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482–94
   PubMed Web of Science ®Google Scholar
• Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanism in platelets. Arterioscler Thromb Vasc Biol 2008;28:403–12
   PubMed Web of Science ®Google Scholar
• Frishman WH, Burns B, Atac B, et al. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995;130:877–92
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–619
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139–228
   PubMed Web of Science ®Google Scholar
• Cheng JW. Updates in Antiplatelet agent used in cardiovascular diseases. J Cardiovasc Pharmacol Ther 2012;18:514–24
   Web of Science ®Google Scholar
• Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297:2018–24
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008;156(2 Suppl):S10–15
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Metha SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. N Engl J Med 2001;345:494–502
   PubMed Web of Science ®Google Scholar
• Mehta RS, Yusuf S, Peters JG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33
   PubMed Web of Science ®Google Scholar
• Savi P, Combalbert J, Gaich C, et al. The antiaggregation activity of clopidogrel is due to a metabolic activation by the hepatic cytocrome P450-1A. Thromb Haemost 1994;72:313–17
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;919–33
   PubMed Web of Science ®Google Scholar
• Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010;8:923–33
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Brozovic I, et al. Variability of on treatment platelet reactivity in patients on clopidogrel. Platelets 2014;25:328–36
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Krumphuber J, Jilma B, et al. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease. Br J Pharmacol 2009;159:502–17
   PubMed Web of Science ®Google Scholar
• Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J Thromb Haemost 2007;5:1545–51
   PubMed Web of Science ®Google Scholar
• Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy 2009;29:1089–102
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15
   PubMed Web of Science ®Google Scholar
• EMA Prasugrel Assessment Report [online]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/000984/WC500021975.pdf
   Google Scholar
• Franchi F, Rollini F, Mũniz-Lozano A, et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther 2013;11:1279–91
   PubMedGoogle Scholar
• Waite LH, Phan YL, Spinler SA. Cangrelor: a novel intravenous antiplatelet agent with a questionable future. Pharmacotherapy 2014;34:1061–76
   PubMed Web of Science ®Google Scholar
• Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014;63:619–29
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Welsh RC, Trenk D, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv 2012;5:347–56
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259–74
   PubMed Web of Science ®Google Scholar
• Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514–21
   PubMed Web of Science ®Google Scholar
• Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD1640: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007;17:6013–18
   PubMed Web of Science ®Google Scholar
• Van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556–65
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Lutz DA, Straßburger J, et al. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12-receptor. J Thromb Haemost 2014;12:1898–905
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;31:195–204
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66:487–96
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010;70:65–77
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol 2011;51:978–87
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27:1038–47
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Robert A, et al. Inhibition of Platelet Aggregation by AZD6140, a Reversible Oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–6
   PubMed Web of Science ®Google Scholar
• Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet 2012;6:397–409
   Google Scholar
• Sillen H, Cook M, Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2315–22
   PubMed Web of Science ®Google Scholar
• Teng R. Pharmacokinetic, pharmacodynamic and pharmacocogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 2012;51:305–18
   PubMed Web of Science ®Google Scholar
• Holmberg MT, Tornio A, Joutsi-Korhonen L, et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol 2013;75:1488–96
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol 2012;52:1388–98
   PubMed Web of Science ®Google Scholar
• Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol 2012;1175–82
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–6
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease the ONSET/OFFSET study. Circulation 2009;120:2577–85
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies the RESPOND study. Circulation 2010;121:1188–99
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on plalelet function in patients with acute coronary syndromes. The PLATO (PLATelet inhibition and patient Outcomes) platelet substudy. J Am Coll Cardiol 2010;56:1456–62
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012;60(3):193–9
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013;62:505–12
   PubMed Web of Science ®Google Scholar
• Frelinger ALIII, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013;61:872–9
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Storey R, et al. Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. Am Heart J 2014;168:530–6
   PubMed Web of Science ®Google Scholar
• Tantry S, Bliden K, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: The ONSET/OFFSET and RESPOND Genotype studies. Circ Cardiovasc Genet 2010;3:556–66
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320–8
   PubMed Web of Science ®Google Scholar
• Storey RF, Melissa Thornton S, Lawrance R, et al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets 2009;20:341–8
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA. Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009;124:565–71
   PubMed Web of Science ®Google Scholar
• Peters GR, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140- an oral reversible ADP receptor antagonist Haematologica. 2004;989:14–15
   Google Scholar
• Peters GR, Butler KA, Winter HR. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZP6140. Eur Heart J 2006;27:P4556
   Google Scholar
• Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844–51
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57
   PubMed Web of Science ®Google Scholar
• James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283–93
   PubMed Web of Science ®Google Scholar
• Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672–84
   PubMed Web of Science ®Google Scholar
• Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 2014;35:2083–93
   PubMed Web of Science ®Google Scholar
• Kohli P, Wallentin L, Reyes E, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation 2013;127:673–80
   PubMed Web of Science ®Google Scholar
• James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006–16
   PubMed Web of Science ®Google Scholar
• James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056–67
   PubMed Web of Science ®Google Scholar
• Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131–41
   PubMed Web of Science ®Google Scholar
• Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012;5:680–8
   PubMed Web of Science ®Google Scholar
• James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012;125:2914–21
   PubMed Web of Science ®Google Scholar
• Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013;128:1055–65
   PubMed Web of Science ®Google Scholar
• Alfredsson J, Stenestrand U, Wallentin L, et al. Gender differences in management and outcome in non ST elevation acute coronary syndrome. Heart 2007;93:1357–62
   PubMed Web of Science ®Google Scholar
• Husted S, James SK, Bach RG, et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2014;35:1541–50
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544–54
   PubMed Web of Science ®Google Scholar
• FDA. Ticagrelor Full Prescribing Information [online]. 2013. Available from: www.accessdata.fda.gov/drugsatfda-docs/label/2013/022433s010lbl.pdf
   Google Scholar
• EMA Ticagrelor Assessment Report [online]. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document-library/EPAR-Public_assessment_report/human/001241/WC500100492.pdf
   Google Scholar
• Armstrong A, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014;19:209–19
   PubMed Web of Science ®Google Scholar
• Van Giezen JJ, Sidaway J, Glaves P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012;17:164–72
   PubMed Web of Science ®Google Scholar
• Headrick JP, Lasley RD. Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol 2009;193:189–214
   PubMedGoogle Scholar
• Hausenloy DJ, Bøtker HE, Condorelli G, et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2013;98:7–27
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014;63:2503–9
   PubMed Web of Science ®Google Scholar
• Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013;11:1867–76
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014;63:872–7
   PubMed Web of Science ®Google Scholar
• Wihlborg AK, Wang L, Braun OO, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004;24:1810–15
   PubMed Web of Science ®Google Scholar
• Högberg C, Svensson H, Gustafsson R, et al. The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol 2010;142:187–92
   PubMed Web of Science ®Google Scholar
• Wang K, Zhou X, Huang Y, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010;104:609–17
   PubMed Web of Science ®Google Scholar
• Grzesk G, Kozinski M, Navarese EP, et al. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res 2012;130:65–9
   PubMed Web of Science ®Google Scholar
• Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013;61:723–7
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Moulias A, Koutsogiannis N, et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non–ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention an exploratory study. Circ Cardiovasc Interv 2013;6:277–83
   PubMed Web of Science ®Google Scholar
• Torngren K, Ohman J, Salmi H, et al. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 2013;124:252–8
   PubMed Web of Science ®Google Scholar
• Nanhwan MK, Ling S, Kodakandla M, et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol 2014;34:2078–85
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Lundberg MH, Chan MV, et al. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci USA 2013;110:15782–7
   PubMed Web of Science ®Google Scholar
• Patil SB, Jackman LE, Francis SE, et al. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol 2010;30:2385–91
   PubMed Web of Science ®Google Scholar
• Sürer S, Toktas F, Ay D, et al. Effect of the P2Y12 antagonist ticagrelor on neointimal hyperplasia ina rabbit carotid anastomosis model. Interact Cardiovasc Thorac Surg 2014;19:198–204
   PubMedGoogle Scholar
• Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing non urgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 2012;5:336–46
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012;108:1024–7
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost 2012;108:1031–6
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Sibbing D, DiNicolantonio JJ. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology 2014;127:20–4
   PubMed Web of Science ®Google Scholar
• Storey R, Bliden K, Patil S, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;13:185–93
   Google Scholar
• Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol 2011;108:1542–6
   PubMed Web of Science ®Google Scholar
• Levin LÅ, Wallentin L, Bernfort L, et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value Health 2013;16:574–80
   PubMed Web of Science ®Google Scholar
• Parodi G, Storey R. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care 2014. [Epub ahead of print]
   Google Scholar
• Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol 2011;57:1908–16
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. Clin Pharmacol Ther 2012;91:264–71
   PubMed Web of Science ®Google Scholar
• Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor; cytocrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 2011;39:703–10
   PubMed Web of Science ®Google Scholar
• Teng R, Mitchell PD, Butler K. Pharmacokinetic interaction studies of coadministration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013;69:477–87
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol 2013;69:1801–8
   PubMed Web of Science ®Google Scholar
• Teng R, Kujacic M, Hsia J. Pharmacokinetic interaction study of ticagrelor and cyclosporine healthy volunteers. Clin Drug Investig 2014;34:529–36
   PubMed Web of Science ®Google Scholar
• Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J 2013;34:220–8
   PubMed Web of Science ®Google Scholar
• Liew D, DeAbreu Lourenço R, Adena M, et al. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Clin Ther 2013;35:1110–17
   PubMed Web of Science ®Google Scholar
• Janzon M, James S, Cannon CP, et al. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart 2015;101:119–25
   PubMed Web of Science ®Google Scholar